Sebeková K, Fedelesová V, Blazícek P, Dzúrik R
Medical Bionics Research Institute, Center of Clinical Pharmacology, Bratislava, Czechoslovakia.
Cor Vasa. 1990;32(4):274-81.
In a cross-over study, the effect of 25 mg urapidil infusion (U, Ebrantil 25, Byk-Gulden, FRG) on serotonin (5HT) metabolism and platelet aggregation (PA) was compared with the effect of placebo (P) in 7 patients with essential hypertension. No changes in 5HT and 5-hydroxyindolacetic acid (5HIAA) plasma levels and platelet 5HT content were observed. PA induced ex vivo by ADP decreased significantly. 5HIAA urinary excretion and fractional excretion (FE) increased, while 5HT renal metabolism changed only moderately. No changes in adrenaline and noradrenaline excretion were observed. In in vitro studies, U in therapeutic levels decreased ADP-induced PA and completely inhibited 5HT-induced PA (platelets of healthy volunteers). It is suggested that U has a direct antiaggregatory effect through 5HT2 receptors of platelets.
在一项交叉研究中，将25毫克乌拉地尔输注（U，Ebrantil 25，Byk-Gulden，德国）对血清素（5HT）代谢和血小板聚集（PA）的影响与安慰剂（P）对7例原发性高血压患者的影响进行了比较。未观察到5HT和5-羟吲哚乙酸（5HIAA）血浆水平及血小板5HT含量的变化。由ADP体外诱导的PA显著降低。5HIAA尿排泄和排泄分数（FE）增加，而5HT肾脏代谢仅中度改变。未观察到肾上腺素和去甲肾上腺素排泄的变化。在体外研究中，治疗水平的U降低了ADP诱导的PA，并完全抑制了5HT诱导的PA（健康志愿者的血小板）。提示U通过血小板的5HT2受体具有直接的抗聚集作用。
